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Abstract
Background: MicroRNAs (miRNAs) regulate the expression of networks of genes and their dysregulation is well
documented in human malignancies; however, limited information exists regarding the impact of miRNAs on the
development and progression of osteosarcoma (OS). Canine OS exhibits clinical and molecular features that closely
resemble the corresponding human disease and it is considered a well-established spontaneous animal model to
study OS biology. The purpose of this study was to investigate miRNA dysregulation in canine OS.
Methods: We evaluated miRNA expression in primary canine OS tumors and normal canine osteoblast cells using the
nanoString nCounter system. Quantitative PCR was used to validate the nanoString findings and to assess miR-9
expression in canine OS tumors, OS cell lines, and normal osteoblasts. Canine osteoblasts and OS cell lines were stably
transduced with pre-miR-9 or anti-miR-9 lentiviral constructs to determine the consequences of miR-9 on cell
proliferation, apoptosis, invasion and migration. Proteomic and gene expression profiling of normal canine osteoblasts
with enforced miR-9 expression was performed using 2D-DIGE/tandem mass spectrometry and RNA sequencing and
changes in protein and mRNA expression were validated with Western blotting and quantitative PCR. OS cell lines
were transduced with gelsolin (GSN) shRNAs to investigate the impact of GSN knockdown on OS cell invasion.
Results: We identified a unique miRNA signature associated with primary canine OS and identified miR-9 as being
significantly overexpressed in canine OS tumors and cell lines compared to normal osteoblasts. Additionally, high
miR-9 expression was demonstrated in tumor-specific tissue obtained from primary OS tumors. In normal osteoblasts
and OS cell lines transduced with miR-9 lentivirus, enhanced invasion and migration were observed, but miR-9
did not affect cell proliferation or apoptosis. Proteomic and transcriptional profiling of normal canine osteoblasts
overexpressing miR-9 identified alterations in numerous genes, including upregulation of GSN, an actin
filament-severing protein involved in cytoskeletal remodeling. Lastly, stable downregulation of miR-9 in OS cell lines
reduced GSN expression with a concomitant decrease in cell invasion and migration; concordantly, cells transduced
with GSN shRNA demonstrated decreased invasive properties.
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Conclusions: Our findings demonstrate that miR-9 promotes a metastatic phenotype in normal canine osteoblasts
and malignant OS cell lines, and that this is mediated in part by enhanced GSN expression. As such, miR-9 represents a
novel target for therapeutic intervention in OS.
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Background
Osteosarcoma (OS) is the most common form of malignant
bone cancer in dogs and children, although the incidence
of disease in the canine population is approximately ten
times higher than in people [1–3]. Both clinical and mo-
lecular evidence suggest that human and canine OS share
many key features, including anatomic location, presence of
microscopic metastatic disease at diagnosis, development of
chemotherapy-resistant metastases, altered expression/acti-
vation of several proteins (e.g. Met, PTEN, STAT3), and
p53 inactivation, among others [2, 3]. Additionally, canine
and pediatric OS exhibit overlapping transcriptional profiles
and shared DNA copy number aberrations, supporting the
notion that these diseases possess significant similarity at
the molecular level [4–7]. A defining feature of OS in both
species is the high rate of early microscopic metastatic
disease. The adoption of multidrug chemotherapy protocols
and aggressive surgical techniques has improved survival;
however, approximately 30 % of children and over 90 % of
dogs ultimately die from metastasis and there has been no
significant improvement in clinical outcome in both species
over the past 20 years [3, 8].
MicroRNAs (miRNAs) are small non-coding RNAs
that negatively regulate gene expression at the post-
transcriptional level, resulting in either mRNA cleavage
and/or translational repression. Their functions extend
to both physiological and pathological conditions,
including cell fate specification, cell death, development,
metabolism, and cancer [9, 10]. Aberrant miRNA
expression is commonly associated with human cancers
and it is well established that miRNAs can play a causal
role in tumorigenesis, functioning as tumor suppressors
or oncogenes by targeting genes involved in tumor
development, progression or metastasis [11, 12]. As
miRNAs can affect multiple genes in a molecular path-
way, or within the context of a network, they likely
regulate many distinct biological processes relevant to
normal and malignant cell homeostasis [13, 14]. Fur-
thermore, experimental data demonstrate that targeting
miRNA expression using chemically modified oli-
gonucleotides can efficiently block the function of miR-
NAs deregulated in malignant cells and alter cancer
phenotypes, establishing the rationale for targeting
miRNAs therapeutically in some cancers [15–17]. A
variety of miRNA formulations and target-specific deliv-
ery strategies have accelerated the clinical development
of antisense miRNAs (antago-miRs) or miRNA mimics,
several of which have entered human clinical trials. For
example, Miravirsen (Santaris Pharma) and MRX34
(Mirna Therapeutics) are being evaluated in patients
with chronic hepatitis C virus infection, primary liver
cancer, and metastatic cancer that has spread to the liver
[18, 19].
Altered miRNA expression profiles have been identified
in human OS and unique miRNA signatures are associ-
ated with risk of metastasis and response to chemotherapy
in this disease [20–27]. Studies evaluating miRNA dysreg-
ulation in naturally occurring canine cancers demonstrate
that similar to their human counterpart, aberrant miRNA
expression likely contributes to tumor biology, although
few studies have investigated their contribution to canine
OS [28–31]. In human OS, dysregulated miRNAs have
been shown to play a direct role in promoting cell pro-
liferation, evading apoptosis, and enhancing motility and
invasion. For example, decreased expression of miR-183
in human OS tissues correlates with lung metastasis and
local recurrence, in part due to targeting of the
membrane-cytoskeleton linker ezrin by miR-183 [32–34].
MiR-125b is frequently down-regulated in human OS
tumors and OS cell lines and promotes OS cell proli-
feration and migration in vitro and tumor formation in
vivo by regulating expression of the functional down-
stream target STAT3 [35].
Recent work has demonstrated down-regulation of a
large number of miRNAs at the 14q32 locus in human
OS tumors compared to normal bone tissue, osteoblasts
and other types of sarcoma [36–38]. Transcript levels of
the regulatory gene, c-MYC, are controlled by miRNAs
at the 14q32 locus, and reinstating functional levels of
these 14q32 miRNAs decreases c-MYC activity and
induces apoptosis in Saos2 cells [36]. Consistent with
findings in human OS, cross-species comparative
analysis found decreased expression of miR-134 and
miR-544 (orthologous to the human 14q32 miRNA
cluster) in canine OS tumors compared to reactive
canine osteoblasts [37]. Furthermore, reduced expression
of 14q32 miRNAs in human OS tumors and orthologous
miR-134 and miR-544 in canine OS is associated with
shorter survival, suggesting that dysregulation of the
14q32 miRNA cluster may represent a conserved mech-
anism contributing to the aggressive biological behavior
of OS in both species.
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Given that canine OS is often used as a spontaneous
large animal model of the human disease to test novel
therapeutic approaches that may affect the course of
microscopic metastasis, a detailed understanding of the
shared molecular mechanisms would be ideal to more
accurately inform future clinical studies. As such, the
purpose of this study was to compare the miRNA
expression profiles in primary OS tumor samples and
normal osteoblasts to identify key miRNAs that may be
contributing to the biologic aggressiveness of canine OS.
Methods
Cell lines, primary cell cultures, primary tumor samples
Canine OS cell lines OSA8 and OSA16 [5] were maintained
in RPMI-1640 (Gibco Life Technologies, Grand Island, NY,
USA) supplemented with 10 % fetal bovine serum, non-
essential amino acids, sodium pyruvate, penicillin, strepto-
mycin, L-glutamine, and HEPES (4-(2-dydroxethyl)-1-
piperazineethanesulfonic acid) at 37 °C, supplemented with
5 % CO2 (media supplements from Gibco). Normal canine
osteoblasts (catalog no. Cn406-05) Cell Applications Inc,
San Diego, CA, USA) were cultured in canine osteoblast
medium (Cell Applications Inc, catalog no. Cn417-500).
Primary canine osteoblast cultures were generated from
trabecular bone isolated from the femoral heads of dogs
undergoing total hip arthroplasty or femoral head ostect-
omy at the Ohio State University Veterinary Medical
Center (OSU-VMC) as previously described [39]. Briefly,
femoral heads were washed in buffered saline and trabecu-
lar bone was curetted to remove bone chips. Bone chips
were washed and digested in serum-free Dulbecco’s
modified Eagle medium (DMEM)/F12K medium (Gibco)
supplemented with 239 U/mL collagenase type XI (Sigma,
St. Louis, MO, USA), 2 mM L-glutamine, 50 μg/mL
pencillin-streptomycin and transferred to a spinner flask
in a humidified incubator at 37 °C with 5 % CO2 for 3–
4 h. Following digestion of cellular material, the bone frag-
ments were washed with buffered saline and plated into
T25 flasks in calcium-free DMEM/F12 medium supple-
mented with 10 % fetal bovine serum, 50 μg/mL ascorbate
(Sigma), 50 μg/mL pencillin-streptomycin, and 2 mM L-
glutamine with changes of medium every 3–4 days.
Osteogenic induction of confluent monolayer cultures was
accomplished using DMEM/F12 (Gibco) medium supple-
mented with 10 % fetal bovine serum, 0.1 μM dexametha-
sone (Sigma), 10 mM β-glycerophosphate (Sigma), 50 μg/
mL ascorbate (Sigma), 50 μg/mL pencillin-streptomycin,
and 2 mM L-glutamine for 21 d with medium changes
every 3–4 days [40]. Control cultures were maintained
without osteogenic supplements. Cultures were evaluated
for alkaline phosphatase expression using the Leukocyte
Alkaline Phosphatase Kit (Sigma) according to the manu-
facturer’s instructions. The protocol for generation of
canine osteoblasts was approved by the OSU Institutional
Animal Care and Use Committee (IACUC, protocol
2009A0184). Normal canine tissue collections were
approved by the OSU IACUC (protocol 2010A0015).
Fresh frozen canine OS tumor samples were obtained
from dogs presenting to the OSU-VMC and from Dr.
Jaime Modiano at the University of Minnesota (UMN)
Veterinary Medical Center. Tumor sample collections
were performed in accordance with established hospital
protocols and approved by the respective IACUCs at both
OSU and UMN. Clinical patient data, including age, sex,
breed, histopathological diagnosis, and primary tumor
location is detailed in Additional file 1: Table S1.
RNA isolation, cDNA synthesis, RT-PCR and quantitative
real-time PCR
RNA was extracted from normal fresh frozen canine
tissues (brain cortex, bone, liver, lymph node, kidney,
skeletal muscle, spleen, thyroid), primary canine osteoblast
cultures, osteoblast cells, OS cell lines, and fresh frozen
primary OS tumors using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. To confirm bone marker expression in pri-
mary osteoblast cultures, cDNA was generated using 1 μg
of total RNA using Superscript III (Invitrogen) and 1/20
of the resultant cDNA was used for each PCR reaction in
a total volume of 25 μl. Primers designed and utilized for
canine ALP, BMP2, OP, and GAPDH are listed in Table 1.
Standard PCR was performed with all primer sets and
amplicon length verified by agarose gel electropohoresis
and visualization of products using the Alpha Imager
system (Alpha Innotech Corp, San Leandro, CA, USA).
Real-time PCR was performed using the Applied
Biosystems StepOne Plus Detection System (Applied
Biosystems, Foster City, CA, USA). Human Taqman
miRNA assays (Applied Biosystems) were used accord-
ing to manufacturer’s instructions to quantify mature
miRNA levels in available canine cell lines and tissues
(miR-1, miR-9, miR-10b, miR-29a, miR-122, miR-126,
miR-199b, miR-200c, miR-451; all mature miRNAs share
100 % sequence homology between dogs and humans).
MiRNA-specific primers were used to convert 50 ng
total RNA to first-strand cDNA, followed by real-time
PCR with TaqMan probes. All samples were normalized
to U6 snRNA. To validate changes in mRNA expression
for selected genes affected by miR-9 expression, total
RNA was collected and cDNA was generated as
described above. Canine GSN and TGFBI mRNA was
detected using Fast SYBR green PCR master mix
(Applied Biosystems) according to the manufacturer’s
protocol and primer sets are detailed in Table 1.
Normalization was performed relative to 18S rRNA. All
reactions were performed in triplicate and included no-
template controls for each gene. Relative gene expres-
sion for all real-time PCR data was calculated using the
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comparative threshold cycle method [41]. Experiments
were repeated 3 times using samples in triplicate.
Quantitative real-time PCR analysis of formalin-fixed
paraffin-embedded canine primary osteosarcoma tumor
samples
Formalin-fixed paraffin-embedded (FFPE) primary canine
OS tissues were obtained from the OSU-VMC Biospecimen
Repository. H&E stained sections from a single random
block from each patient were reviewed by a pathologist
(OHI) to define and mark representative OS tumor regions.
Using the marked H&E stained glass slide as a map, the
corresponding areas of the unstained FFPE tissue block
were identified and 15 targeted core samples of each can-
cerous tissue region were obtained. Tumor cores were then
processed and RNA was isolated using the RecoverAll™
Total Nucleic Acid Isolation Kit for FFPE (Applied Biosys-
tems) according to manufacturer’s recommendations. To
quantify miR-9 expression, cDNA was generated and real-
time PCR was performed using Human Taqman miRNA
assays (Applied Biosystems) as described above.
MiRNA expression profiling
MiRNA expression profiling of normal canine tissues (brain
cortex, liver, lymph node, kidney, skeletal muscle, spleen,
thyroid), 72 fresh primary OS tumors, 2 primary osteoblast
cultures, and canine osteoblast cells (Cell Applications) was
performed at the OSU Comprehensive Cancer Center
Genomics Shared Resource using the multiplexed nano-
String nCounter miRNA system (nanoString Technologies,
Seattle, WA, USA) according to manufacturer’s protocol
[42]. Total RNA (100 ng) was used as input material. Small
RNA samples were prepared by ligating a specific DNA tag
onto the 3’ end of each mature miRNA according to manu-
facturer’s instruction (nanoString Technologies). These tags
normalized the melting temperatures of the miRNAs and
provided identification for each miRNA species in the
sample. Excess tags were then removed and the resulting
material was hybridized with an nCounter Human (V2)
miRNA Expression Assay CodeSet containing a panel of
miRNA:tag-specific nCounter capture and barcoded
reporter probes. Hybridization reactions were incubated at
65 °C overnight. Hybridized probes were purified and
immobilized on a streptavidin-coated cartridge using the
nCounter Prep Station (nanoString Technologies). nCoun-
ter Digital Analyzer was used to count individual fluores-
cent barcodes and quantify target RNA molecules present
in each sample. For each assay, a high-density scan (600
fields of view) was performed.
NanoString data analysis
Abundances of miRNAs were quantified using the nano-
String nCounter gene-expression system [42]. Boxplot
analysis did not detect obvious batch effect or poor sample
integrity; therefore, all data were used for analysis. Raw
data was normalized using internal positive control probes
included in each assay and then a filtering step was
applied. Internal negative control probes were used to
determine a background threshold (2 standard deviations
above the mean negative control probe count value) and if
more than 90 % of the samples had miRNA expression
lower than the background threshold cutoff value, those
miRNAs were filtered out. After data filtering, a total of
519 miRNAs were used for analysis. Filtered data was
quantile normalized and linear regressions were used to
compare miRNA expression between tumor samples and
normal osteoblast samples. A p-value of 1/519 = 0.0019
was used as a cutoff to claim for significance if controlling
1 false positive among the 519 tested miRNAs. Differential
miRNA expression was determined by one-way analysis of
variance (ANOVA) and p-values of <0.0019 were consid-
ered statistically significant.
miR-9, anti-miR-9, and shGSN lentivirus infection
Lentiviral constructs obtained from Systems Biosciences
(Mountain View, CA, USA) were packaged using the
pPACKH1 Lentivector Packaging KIT (catalog no. LV500A-
1) according to manufacturer’s instructions. Canine osteo-
blast cells (Cell Applications Inc.) and OSA16 cells (5 × 105)
were transduced with negative control empty lentivirus
(catalog no. CD511B-1) or pre-miR-9-3 lentivirus (catalog
no. PMIRH9-3PA-1). For reciprocal knock-down experi-
ments, canine OSA8 cells (5 × 105) were transduced with
pGreenPuro Scramble Hairpin Control lentivirus (catalog
Table 1 Primer sequences
Primers Primer sequences
Canine ALP 245F 5’-CAT ACA ACA CCA ACG CTC AGG-3’
Canine ALP 582R 5’-GAC GTT GTG CAT GAG CTG GTA GGC-3’
Canine OPN 130F 5’-GTA AGT CCA ATG AAA GCC ATG ACG-3’
Canine OPN 468R 5’-CAT TGA AGT CAT CTT CCA TAC TC-3’
Canine OC 001F 5’-CAG CCT TCG TGT CCA AG-3’
Canine OC 193R 5’-GCC ATA GAA GCG CTG GTA AG-3’
Canine BMP2 151F 5’-GAG TCC GAG TTG CGG CTG CTC AG-3’
Canine BMP2 475R 5’-GTT CCT GCA TCT GTT CCC G-3’
Canine GSN 387F 5’-CTG CCA TCT TCA CGG TGC AGC-3’
Canine GSN 549R 5’-CAC GAC TTC ATT GGG GAC CAC GTG C-3’
Canine TGFBI 1771F 5’-GACATGCTCACCATCAACGG-3’
Canine TGFBI 1919R 5’-GCTGTGGAAACATCAGACTCTGCAG-3’
K9 GAPDHF 5’-GTCCATGCCATCACTGCCACCCAG-3’
K9 GAPDHR 5’-CTGATACATTGGGGGTGGGGACAC-3’
GAPDHF 5’-ACC ACA GTT CCA TGC CAT CAC-3’
GAPDHR 5’-TCC ACC ACC CTG TTG CTG TA-3’
18S V2F 5’-AAA TCC TTT AAC GAG GAT CCA TT-3’
18S V2R 5’-AAT ATA CGC TAT TGG AGC TGG A-3’
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no. MZIP000-PA-1) or miRZip-9 anti-miR-9 lentivirus
(catalog no. MZIP9-PA-1). Briefly, 5 × 105 cells were plated
and left overnight in 10 % serum-containing medium. The
following day, the medium was changed to Stemline (Gibco)
with transfection agent TransDux (Systems Biosciences) and
either empty control or pre-miR-9-3 virus (osteoblasts) or
miRZip-9 or negative control scrambled virus (OSA8) was
added to cells according to manufacturer’s protocol. FACS-
mediated cell sorting based on GFP expression was
performed 72 h post-transduction and miR-9 expression
was evaluated by real-time PCR (Applied Biosystems).
Stable knock down of gelsolin (GSN) was performed
using short hairpin RNA (shRNA) lentiviral constructs
(pLKO.1:Hygro-shScramble and pLKO.1:Hygro-shGSN)
and high-titer lentiviral stocks were generated as described
in the Addgene's pLKO.1 protocol. pLKO.1:hygro plasmid
was a kind gift from Bob Weinberg (Addgene plasmid
#24150). Briefly, 1 × 105 OSA8 cells were plated and left
overnight in 10 % serum-containing medium. The follow-
ing day, the medium was replaced with serum-free medium
and target cells were infected with transfection agent
TransDux (Systems Biosciences) and either pLKO.1:Hygro-
Scramble or pLKO.1:Hygro-shGSN virus or TransDux
alone for 24 h. Cells were cultured for 7–10 days in 10 %-
serum-containing medium supplemented with 75 ug/mL
Hygromycin-B (Life Technologies) for plasmid selection.
Knockdown of GSN was confirmed by quantitative real-
time PCR and Western blotting Cells were collected and
processed for Western blotting as described below to detect
levels of GSN and efficiency of knock down. Sequences of




To assess the effects of miR-9 and GSN on invasion, cell
culture inserts (8-μm pore size; Falcon) were coated with
100 μL of diluted (1:10) Matrigel (BD Bioscience, San
Jose, CA, USA) to form a thin continuous layer and
allowed to solidify at 37 °C for 1 h. Canine osteoblasts,
OSA8 and OSA16 cell lines (5 × 104/mL) transduced with
control lentivirus, pre-miR-9-3 lentivirus, miRZip-9
lentivirus, or shGSN lentivirus were prepared in serum-
free medium and seeded into each insert (upper chamber)
and medium containing 10 % fetal bovine serum was
placed in the lower chamber. The cells were incubated for
24 h to permit invasion through the Matrigel layer. Cells
remaining on the upper surface of the insert membrane
were wiped away using a cotton swab, and cells that had
migrated to the lower surface were stained with crystal
violet and counted in ten independent 20× high powered
fields for each Matrigel insert. Experiments were repeated
3 times using samples in triplicate.
Wound healing assay
To evaluate the effects of miR-9 on cell migration, canine
osteoblasts transduced with control lentivirus or pre-miR-
9-3 lentivirus and OSA8 cells transduced with scrambled
control lentivirus or miRZip-9 lentivirus were seeded in
complete medium and grown until confluent in 6-well
plates. A gap was introduced in the cells by scraping with
a P200 pipette tip and cells were placed in fresh medium
containing 10 % fetal bovine serum. After 20 h (OSA8) or
24 h (osteoblasts), migration across the gap was evaluated
by digital photography. Each experiment was repeated 3
times.
Cell proliferation
Canine osteoblasts and OSA16 cells (2.5 × 103) transduced
with control lentivirus or pre-miR-9-3 lentivirus were
seeded in triplicate in 96-well plates; non-transduced cells
served as negative controls. After 24, 48, or 72 h of culture,
media was removed and plates were frozen at −80 °C over-
night before processing with the CyQUANT® Cell Prolifer-
ation Assay KIT (Molecular Probes, Eugene, OR, USA)
according to the manufacturer’s instructions. Fluorescence
was measured using a SpectraMax microplate reader
(Molecular Devices, Sunnyvale, CA, USA). Cell prolifera-
tion was calculated as a percentage of non-transduced
control cells. Each experiment was repeated 3 times.
Detection of Apoptosis/Caspase 3/7 activity
Induction of apoptosis was assessed using the Senso-Lyte®
Homogeneous AMC Caspase- 3/7 Assay KIT (Anaspec
Inc., San Jose, CA, USA) as previously described [43].
Canine osteoblasts and OSA16 cells (2.5 × 103) trans-
duced with either empty lentivirus or pre-miR-9-3 lenti-
virus were plated in triplicate in 96-well plates for 24 and
48 h prior to analysis. Fluorescence was measured on a
SpectraMax microplate reader (Molecular Devices) and
caspase 3/7 activity was reported after subtraction of
background fluorescence elicited by medium alone. Each
experiment was repeated 3 times.
2D-DIGE and protein identification by LC-MS/MS
Protein lysates prepared from canine osteoblast cells
transduced with either empty lentivirus (n = 4) or pre-
miR-9-3 lentivirus (n = 4) were purified using the 2-D
Clean-Up Kit (GE Healthcare, Uppsala, Sweden).
Samples were suspended in 100 μL of lysis buffer (30 M
Tris pH 8.5, 7 M Urea, 2 M Thiourea, 4 % CHAPS) and
quantitated by Bradford assay. Two-dimensional differ-
ence gel electrophoresis (2D-DIGE) was performed as
previously described [44]. Briefly, internal control
samples were prepared by mixing a portion of all
individual samples. Pooled internal control standards
(50 μg) were labeled with Cy2 dye and individual
samples (50 μg) were labeled with the appropriate Cy3
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or Cy5 dye (GE Healthcare) according to the manufac-
turer's instructions, mixed and separated by two-
dimensional difference gel electrophoresis. The first
dimension separation was achieved using IPG isoelec-
tric focusing strips (24 cm length, pH 3–10; GE Health-
care). The second dimension separation was achieved
by SDS-PAGE on large-format gels (20x24cm) using a
Dalt 12 electrophoresis system (GE Healthcare). Gels
were scanned using a Typhoon 9400 variable mode
scanner (GE Healthcare) at appropriate wavelengths.
Gel images were analyzed and relative protein
abundance was performed using SameSpots software
(TotalLabs). Background subtraction, quantification
and normalization were automatically applied with low
experimental variation. The student’s t-test was used to
compare protein expression for each spot between
empty vector and miR-9-transduced osteoblast samples
and p-values of < 0.05 were considered significant.
Protein spots of interest were located and excised from
separate preparative gels using the Ettan Spot Handling
Workstation (GE Healtchare) according to manufac-
turer’s instructions. Gel pieces containing protein spots
were cored, digested with trypsin (Promega, Madison, WI,
USA), and subjected to capillary-liquid chromatography-
nanospray tandem mass spectrometry (Nano-LC/MS/MS)
using a Thermo Finnigan LTQ mass spectrometer equipped
with a nanospray ion source. The LC system used was an
UltiMate™ Plus from LC-Packings A Dionex Co (Sunnyvale,
CA, USA) with a Famos autosampler and Switchos column
switcher. Mascot Daemon software (version 2.2; Matrix
Science, Boston, MA, USA) was used to search for the mass
of the peptide ion against other mammalian proteins in the
NCBI database (1,391,110 sequences). Protein identifica-
tions were checked manually and proteins with a Mascot
score of 100 or higher with a minimum of two unique
peptides from one protein having a -b or -y ion sequence
tag of five residues or better were accepted.
RNA Sequencing
Total RNA was extracted from canine osteoblast cells
transduced with either empty lentivirus (n = 3) or pre-miR-
9-3 lentivirus (n = 3) using the TRIzol method and RNA
sequencing was performed at the OSU Comprehensive
Cancer Center Genomics Shared Resource. Briefly, total
RNA was treated by Ribo-Zero Gold Subtraction reagents
from TruSeq stranded total RNA (Illumina; RS-122-2201)
to remove cytoplasmic and mitochondrial rRNAs and for
the subsequent construction of the RNA-seq library
according to the manufacturer’s instructions. Stranded total
transcriptome libraries were quantified and qualified by
Qubit and RIN analysis, respectively. Sequencing was
performed on an Illumina HiSEq. 2500 instrument at a
depth of ∼ 40 million paired-end, 100 bp long, strand-
specific reads per sample. AdapterRemover was used to
trim adapter sequences and the remaining reads were
aligned using STAR to the canFam3 genome. Quality
control was done using RNA-SeQC, in order to check for
samples needing additional sequencing reads. Differential
expression was determined using two different
pipelines. First, gene expression counts were generated
by HTSeq-Count and fed into DESeq2, which com-
pared several sample groups using a likelihood-ratio
test (LRT). Second, expression of individual transcripts
was quantified by cuffquant with comparisons between
pairs of conditions performed by cuffdiff.
Statistical analysis relative to mRNA expression data was
performed using CuffDiff Software. Differential gene ex-
pression was determined by student’s t-test and p-values of
<0.05 were considered statistically significant. Prediction of
miR-9 binding to the 3’-UTR of genes down-regulated by
miR-9 was performed with computer-aided algorithms ob-
tained from TargetScan (http://www.targetscan.org), PicTar
(http://pictar.mdc-berlin.de), miRanda (http://www.micror-
na.org), and miRWalk (http://www.umm.uni-heidelberg.de/
apps/zmf/mirwalk).
Immunoblotting
Protein lysates from canine osteoblasts transduced with
control or pre-miR-9-3 lentivirus and OSA8 cells stably
expressing scramble or miRZip-9 lentiviral constructs
were prepared and quantified, separated by SDS-PAGE,
and western blotting was performed as previously de-
scribed [43]. The membranes were incubated overnight
with anti-gelsolin antibody (D9W8Y, catalog no. 12953,
Cell Signaling Technology, Danvers, MA) then incu-
bated with the appropriate horseradish peroxidase linked
secondary antibodies, washed, and exposed to substrate
(SuperSignal West Dura Extended Duration Substrate,
Pierce, Rockford, IL). Blots were stripped, washed, and
reprobed for β-actin (Santa Cruz Biotechnology, Santa
Cruz, CA).
Statistics
Whenever possible, experiments were performed in tripli-
cate and repeated 3 times. Data were presented as mean
plus or minus standard deviation. Real time PCR miRNA
or gene expression data was first normalized to internal
control (U6 snRNA and 18S, respectively) and the delta
delta Ct method [41] was used to compare miRNA expres-
sion by one-way ANOVA. For analysis of invasion assay
data, a linear mixed effects model was used to take account
of the correlations among observations run in the same
biological replicate. Group comparisons in the CyQUANT®
proliferation assays, caspase 3/7 activity, and invasion
assays were analyzed by ANOVA. Values of p < 0.05 were
considered statistically significant.
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Results
A unique miRNA expression signature is associated with
primary canine OS
To characterize miRNA expression in canine OS and evalu-
ate the role of miRNA dysregulation in OS pathogenesis, it
was first necessary to validate a method to analyze differen-
tial expression. The Human (V2) miRNA Expression Assay
CodeSet was used to profile a panel of seven normal canine
tissues (brain cortex, liver, lymph node, kidney, skeletal
muscle, spleen, thyroid; N = 3 per tissue). Because of the
high degree of sequence conservation of miRNAs across
humans and dogs, 168 miRNAs on the human panel have
sequences identical to canine miRNAs (miRBase v.15). A
high abundance of tissue-specific miRNAs (see Additional
file 2: Figure S1) were detected and real-time PCR was used
to validate this finding (see Additional file 3: Figure S2).
These miRNA abundance data from normal canine tissues
establish that the nanoString nCounter platform is a valid
high-throughput methodology to study miRNA expression
in canine samples.
To generate normal cells for comparison to osteosar-
coma cells, primary osteoblast cultures were differentiated
in vitro from canine mesenchymal stem cells. These cells
were confirmed to express alkaline phosphatase and other
bone-specific markers (Additional file 4: Figure S3). Global
miRNA expression in fresh primary canine OS tumor
samples (N = 72), primary osteoblast cultures (N = 2), and
normal osteoblast cells (commercially available, N = 1)
was evaluated using the nanoString nCounter platform. A
distinct miRNA expression signature composed of 70
differentially expressed miRNAs was identified in primary
canine OS tumor samples compared to canine osteoblast
cells or primary osteoblast cultures (Fig. 1). We found 26
miRNAs that were significantly overexpressed in canine
OS tumor samples compared to canine osteoblast cells or
primary osteoblast cultures, while 44 miRNAs were down-
regulated in OS tumor tissues (Table 2). To validate these
findings, real-time PCR confirmed differential expression
for 4 of the 70 significant OS miRNAs among a random
sampling of 16 fresh OS specimens and 5 control
osteoblast cultures (Fig. 2). Specifically, we verified the
overexpression of miR-126, miR-199b, miR-451 in OS
samples relative to normal osteoblasts. In contrast, miR-
29a showed significant down-regulation in primary canine
OS tumor tissues compared to normal osteoblasts.
Furthermore, several differentially expressed miRNAs
identified in our canine OS tumor samples show similar
alterations in human OS tumors (Table 2, bolded).
1.3.2 miR-9 is up-regulated in canine OS tumor tissues
and cell lines
Of the miRNAs found to be dysregulated in canine OS,
miR-9 expression levels were significantly higher in primary
canine tumor samples as compared to normal canine
osteoblasts. This finding was independently validated by
real-time PCR for miR-9 in fresh primary canine OS
tumors, canine OS cell lines, normal canine bone, osteo-
blast cell lines, and primary osteoblast cultures (Fig. 3),
demonstrating significantly higher levels of miR-9 expres-
sion in the tumors and OS cell lines relative to normal bone
or osteoblasts. Primary osteosarcoma tumor specimens
exhibit significant cellular heterogeneity; it was therefore
possible that expression levels of miR-9 in tumor samples
were influenced by the proportion of tumor cells to
stroma/inflammatory cells. To assess the contribution of
tumor microenvironment on miR-9 expression in primary
canine OS tissues, we identified homogenous OS tumor
cells regions in FFPE primary OS tumor specimens and iso-
lated RNA from targeted tumor core samples. We found
that miR-9 expression was markedly increased in OS tumor
cells as compared to normal canine bone, normal canine
osteoblasts and primary osteoblast cultures (Fig. 3). These
findings demonstrate that the observed overexpression of
miR-9 in canine OS tumor samples is not secondary to
non-neoplastic cells infiltrating the tumor microenviron-
ment, but derived directly from the malignant osteoblasts.
These data are concordant with published data demonstrat-
ing overexpression of miR-9 in human OS [45].
Overexpression of pre-miR-9 does not alter cellular
proliferation or caspase-3,7 dependent apoptosis in
normal canine osteoblasts or the OSA16 cell line
To assess the biological consequences of miR-9 expression
in normal osteoblasts or malignant OS cell lines, canine
osteoblasts and the OSA16 cell line that exhibits low
endogenous expression of miR-9 were transduced with a
pre-miR-9-3 lentiviral expression vector. Stably trans-
duced GFP + cells were sorted and real-time PCR was
used to confirm miR-9 overexpression (Fig. 4a). To deter-
mine the impact of miR-9 expression on normal or malig-
nant osteoblast cell proliferation and apoptosis, canine
osteoblasts and the OSA16 cell line expressing control or
pre-miR-9-3 lentiviral constructs were cultured for 24, 48,
and 72 h and cell proliferation and caspase-3,7 activity
was assessed. Overexpression of miR-9 had no observed
effects on cell proliferation or apoptosis in either normal
osteoblast cells or malignant OS cell lines (Fig. 4b, c).
miR-9 expression enhances invasion and migration in
normal osteoblasts and the OSA16 cell line
To investigate the effects of enforced miR-9 expression on
invasive capacity, a standard Matrigel Invasion assay was
performed to evaluate cell invasion. As shown in Fig. 5a,
overexpression of miR-9 in normal osteoblasts or malig-
nant OSA16 cells significantly enhanced their invasion
after 24 h of culture compared to cells expressing empty
vector. Cell migration activity was assessed in normal os-
teoblasts overexpressing miR-9 using the wound-healing
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assay (scratch test). Fig. 5b demonstrates that miR-9
enhanced cell motility and scattering following gap
formation in normal osteoblasts compared to osteoblasts
expressing control vector (Fig. 5b). Collectively, these find-
ings demonstrate that miR-9 promotes an invasive pheno-
type in normal and malignant canine osteoblasts.
Anti-miR-9 expression decreases cell invasion and
migration in OSA8 cells
To determine whether inhibition of miR-9 would impair
cell migration and invasion, the canine OSA8 cell line
that expresses high basal levels of miR-9 was transduced
with miRZip-9 (anti-miR-9) or control lentivirus. Trans-
duced cells were sorted based on GFP expression and
miR-9 expression was assessed by quantitative PCR to
confirm mature miR-9 knockdown (Fig. 5c). In concord-
ance with our findings in normal canine osteoblasts and
OSA16 cells overexpressing miR-9, inhibition of miR-9
in OSA8 cells significantly decreased cell invasion and
migration compared to control cells (Fig. 5c, d), provid-
ing further support for the role of miR-9 in OS invasion.
2D-DIGE electrophoresis and RNA sequencing identifies
miR-9-induced alterations to the proteome and
transcriptome of canine osteoblasts
To gain further mechanistic insight into miR-9-dependent
cell signaling events that may promote the invasive
phenotype of osteoblasts, we analyzed the proteomic and
gene expression profiles of canine osteoblasts expressing
control or miR-9 lentiviral constructs. Two-dimensional
difference-in-gel electrophoresis (2D-DIGE) identified 10
protein spots that were differentially expressed in osteo-
blasts overexpressing miR-9 compared to cells expressing
empty control vector (Additional file 5: Figure S4).
Determination of the proteins located at these spots was
undertaken using in-gel trypsin digestion followed by
Fig. 1 MiRNA expression signature associated with primary canine OS. MiRNA profiling was performed using the nanoString nCounter system to
assess mature miRNA expression in fresh primary canine OS tumors (n = 72), primary canine osteoblast cultures (n = 2), and a canine osteoblast
cell line (n = 1). Supervised hierarchical clustering was performed for 70 miRNAs differentially expressed in primary canine OS tumors (OS)
compared to primary canine osteoblast cultures or cell lines (Ob) as determined by one-way ANOVA comparison test (p < 0.0019)
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tandem mass spectrometry (Table 3). Four of the protein
spots were unable to be definitively identified, and 2 of the
proteins found to be significantly down-regulated follow-
ing miR-9 overexpression did not have putative miR-9
binding sites within their 3’-UTR, implying that miR-9
may indirectly regulate their expression. Interestingly,
miR-9 induced up-regulation of several proteins involved
in actin dynamics and cytoskeletal remodeling, including
gelsolin and cofilin-1. To independently validate these
changes in protein expression, western blotting was
performed for gelsolin, an actin binding protein implicated
in neoplastic transformation and metastasis [46, 47].
Consistent with our 2D-DIGE results, gelsolin (GSN) was
up-regulated in miR-9 expressing osteoblasts (Fig. 6a).
Concordant with these results, GSN protein expression
was substantially reduced following down-regulation of
miR-9 in OSA8 cells transduced with anti-miR-9 vector as
compared to cells expressing control vector (Fig. 6a).
Furthermore, real time PCR demonstrated an increase in
GSN mRNA expression in osteoblasts overexpressing
miR-9 compared to empty vector controls, which was
further validated with RNA sequencing (0.4-fold increase,
p = 0.05) (Fig. 6b).
We compared the gene expression profile of osteoblasts
possessing enforced miR-9 expression to that of cells
expressing empty control vector and observed significant
differences in transcript expression. RNA sequencing
identified 55 transcripts that were significantly up-regulated
(>2-fold) and 139 transcripts were significantly down-
regulated in osteoblasts overexpressing miR-9 (Additional
file 6: Table S2). Consensus binding sites for miR-9 were
identified within the 3’-UTR of 37 genes that were signifi-
cantly downregulated following miR-9 overexpression,
suggesting that miR-9 may regulate the expression of these











Upregulated miRNAs Downregulated miRNAs Downregulated miRNAs
hsa-miR-126 22.8 1.13E-13 hsa-miR-600 −2.2 1.75E-08 hsa-miR-1277 −1.6 7.94E-05
hsa-miR-450a 7.2 1.55E-08 hsa-miR-22 −4.1 3.37E-08 hsa-miR-98 −2.3 0.00011
hsa-miR-451 93.1 1.50E-07 hsa-miR-34a −6.4 5.39E-08 hsa-miR-539 −1.7 0.00011
hsa-miR-30e 3.5 9.21E-06 hsa-miR-640 −1.8 2.27E-07 hsa-miR-1 −7.4 0.00011
hsa-miR-423-3p 3.0 1.93E-05 hsa-miR-655 −2.0 3.93E-07 hsa-miR-664 −1.7 0.00013
hsa-miR-532-3p 3.3 2.21E-05 hsa-miR-518f −1.8 5.51E-07 hsa-miR-770-5p −2.2 0.00015
hsa-miR-92a 2.6 2.89E-05 hsa-miR-143 −5.5 6.43E-07 hsa-miR-29a −2.7 0.00020
hsa-miR-25 2.6 3.13E-05 hsa-miR-145 −5.4 6.79E-07 hsa-miR-365 −2.0 0.00020
hsa-miR-142-3p 6.8 6.52E-05 hsa-miR-1279 −2.1 1.48E-06 ebv-miR-BART11-3p −1.9 0.00024
hsa-miR-497 4.5 7.69E-05 hsa-miR-200a −2.3 4.35E-06 hsa-miR-133a −2.1 0.00026
hsa-miR-499-5p 2.0 8.22E-05 hsa-miR-1283 −2.1 5.00E-06 hsa-miR-617 −1.6 0.00035
hsa-miR-181c 2.8 0.00013 hsa-miR-744 −2.7 6.23E-06 hsa-miR-1262 −1.6 0.00036
hsa-miR-342-3p 2.2 0.00013 hsa-miR-193b −2.2 8.09E-06 hsa-miR-1274b −5.2 0.00049
hsa-miR-362-5p 2.7 0.00015 hsa-miR-490-5p −1.9 1.47E-05 hsa-miR-943 −1.6 0.00051
hsa-miR-144 20.8 0.00018 hsa-miR-1275 −2.5 2.16E-05 hsa-miR-1255a −1.6 0.0012
hsa-miR-195 3.7 0.00026 hsa-miR-193a-3p −2.2 2.18E-05 hsa-miR-579 −1.9 0.0013
hsa-miR-16 2.3 0.00037 hsa-miR-148b −1.9 2.28E-05 hsa-miR-892a −1.5 0.0013
hsa-miR-362-3p 3.0 0.00039 hsa-miR-1178 −2.4 3.22E-05 hsa-miR-125a-3p −1.5 0.0014
hsa-miR-532-5p 2.5 0.00040 hsa-miR-29b −2.7 3.59E-05 hsa-miR-523 −1.6 0.0015
hsa-miR-1225-3p 1.6 0.00050 hsa-miR-346 −1.9 4.18E-05 hsa-miR-1206 −1.5 0.0017
hsa-miR-26b 2.5 0.00052 hsa-miR-192 −1.9 4.28E-05 hsa-miR-506 −1.5 0.0018
hsa-miR-199b-5p 6.2 0.00054 hsa-miR-526a+ −1.8 3.10E-05 hsa-miR-1179 −1.5 0.0019
hsa-miR-197 2.2 0.00067 hsa-miR-518d-5p+
hsa-miR-9 9.2 0.00087 hsa-miR-520c-5p
hsa-miR-592 1.7 0.0014
hsa-miR-19a 2.0 0.0018
Bold indicates miRNAs similarly altered in human OS
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putative target genes (Additional file 6: Table S2, bolded).
The transcripts identified as predicted targets of miR-9 are
involved in a variety of cellular processes, including tran-
scription (transcription factor 19, TCF19 and homeobox
B6, HOXB6), RNA methyltransferases (NOL1/NOP2/Sun
domain family, member 7, NSUN7), cytokinesis/micro-
tubule assembly (protein regulator of cytokinesis 1, PRC1;
kinesin family member 23, KIF23; stathmin 1, STMN1; and
cancer susceptibility candidate 5, CASC5), endopeptidase
activity (membrane metallo-endopeptidase, MME), and
extracellular matrix organization (TGF-β-induced, TGFBI
and collagen type IV, alpha 4–1 and −2, COL4A1,
COL4A2). Interestingly, one of the most significantly
down-regulated genes was TGFBI, an extracellular matrix
protein and known mediator of osteoblast adhesion. TGFBI
has several highly conserved predicted miR-9 binding sites
within the 3’UTR indicating direct regulation of expression
by miR-9. Concordant with our RNA sequencing results,
real time PCR demonstrated downregulation of TGFBI
transcript expression in canine osteoblasts overexpressing
miR-9 (Fig. 6c).
GSN shRNA decreases cell invasion and migration in
canine OSA8 cells
Our previous findings support the notion that miR-9
promotes cell invasion and migration in canine osteo-
blasts, in part, through up-regulation of GSN. Given the
role of gelsolin in the regulation of actin polymerization
and cycling, we designed lentiviral-shRNA for canine
GSN to determine the impact of GSN downregulation
on cell invasion and migration in canine OSA8 cells. Ex-
pression of GSN was significantly reduced in OSA8 cells
transduced with GSN shRNA as evidenced by Western
blotting and quantitative real-time PCR (Fig. 7a, b). Fur-
thermore, downregulation of GSN correlated with a sig-
nificant decrease in cell invasion in canine OSA8 cells
transduced with GSN shRNA as compared to those
transduced with scrambled control shRNA (Fig. 7c)
Fig. 2 Expression of dysregulated miRNAs in canine OS. Real-time PCR was performed to independently validate changes in miRNA expression for 4
representative differentially expressed miRNAs (miR-29a, miR-126, miR-199b, miR-451) in a subset of primary canine osteoblasts cultures, osteoblast cell
line (Ob, n = 5), and fresh primary canine OS tissues (OS, n = 16). Real time PCR confirmed overexpression of miR-126, miR-199b, and miR-451 and
down-regulation of miR-29a expression in canine OS tumors as compared to normal canine osteoblasts (p≤ 0.01). Three independent experiments
were performed and all reactions were run in triplicate
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demonstrating a direct role for GSN in contributing to
the invasive properties of osteosarcoma cells.
Discussion
MiRNAs regulate numerous biological processes and their
functions extend to both physiological and pathological
conditions, including cell fate specification, cell death,
development, and metabolism. Global dysregulation of
miRNAs is a common feature of many human malignan-
cies and miRNAs play an essential role in the develop-
ment and progression of cancer by functioning as tumor
suppressor genes or oncogenes. [11]. Similar to the case in
human cancers, aberrant expression of miRNAs has been
demonstrated in naturally occurring canine cancers
indicating that miRNA dysregulation likely contributes to
tumorigenesis in this species as well [28–31, 37, 48]. While
the identification and function of altered miRNAs has been
demonstrated in carcinomas and hematopoietic neoplasia,
the influence of miRNAs in sarcomagenesis is incompletely
understood. To date, the most detailed work has identified
miRNA signatures associated with the pathogenesis and
progression of human OS [20, 23, 25, 26]. The purpose of
this study was to investigate the potential contribution of
aberrant miRNA expression to the aggressive biological
behavior of canine OS, a well-established spontaneous
model of the human disease, and evaluate the functional
consequences of altered miRNA expression in canine oste-
oblasts and OS cell lines.
We identified a unique miRNA signature associated
with primary canine OS tumors as compared to normal
canine osteoblasts. Significantly, several critical members
of this signature in canine OS tumors have been reported
as aberrantly expressed in human OS tumors [20–22, 49]
or have known functions in human OS cell lines [50–55].
For example, miR-29a is frequently downregulated in
human OS and regulates osteoblastic cell apoptosis by
silencing Bcl-2 and Mcl-1 and inducing E2F1 and E2F3
expression [53]. The miR-34 family induces apoptosis and
cell cycle arrest in a p53-dependent manner and is down-
regulated in primary OS tissue samples and OS cell lines.
Enforced expression of miR-34a in OS cells was found to
decrease expression levels of c-Met and several factors in
the Wnt and notch signaling pathways in vitro and xeno-
graft studies demonstrated that mice injected with stably
transduced miR-34a OS cells had fewer metastases in vivo
[55]. Lastly, overexpression of miR-199b-5p in human OS
cell lines activates Notch signaling and promotes cell pro-
liferation. Transfection with a miR-199b-5p inhibitor di-
minished cell invasiveness and decreased Notch signaling
by reducing HES1 expression [52]. In concordance with
these data, our findings indicate that these miRNAs are
dysregulated in a similar manner in spontaneous canine
OS. A functional approach to evaluate the consequences
of each of these miRNAs in canine OS was outside the
scope of the current study; however, together these find-
ings support the idea that these miRNAs contribute to the
Fig. 3 MiR-9 is highly expressed in primary canine OS tumors and canine OS cell lines. RNA was collected from primary canine osteoblast cultures
(CBDC, n = 5), normal canine osteoblast cell lines (Ob, n = 2, corresponding to 2 different commercially available lots), normal canine bone (n = 5),
canine OS cell lines (n = 8), FFPE canine OS tumor cores (n = 5), and fresh primary canine OS tumors (n = 20) and real-time PCR was performed to
evaluate miR-9 expression. Real time PCR confirmed overexpression of miR-9 in canine OS tumors and OS cell lines as compared to normal canine
osteoblasts (p < 0.001). Three independent experiments were performed and all reactions were performed in triplicate
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development and/or progression of both canine and
human OS.
Our data demonstrate that miR-9 expression is
significantly upregulated in canine primary OS tumors
compared to normal osteoblast cells or primary osteoblast
cultures. Furthermore, we found that OS cells isolated
from FFPE canine primary OS tumors express high levels
of miR-9 compared to normal canine bone, canine osteo-
blasts and primary osteoblast cultures, suggesting that in-
creased expression of miR-9 in OS tumors is primarily
influenced by OS tumor cells and not stroma/inflamma-
tory cells present in the tumor microenvironment. These
findings are consistent with recent studies demonstrating
that miR-9 expression is significantly increased in primary
Fig. 4 Overexpression of miR-9 has no effect on cell proliferation or apoptosis of normal osteoblasts or OS cell lines. a Normal canine osteoblasts and
OSA16 cells transduced with pre-miR-9-3 lentivirus or empty vector control were sorted to greater than 95 % purity based on GFP expression. MiR-9
levels were assessed by real-time PCR in wild-type, empty vector, and miR-9 expressing cells (Bars: SD. Statistical analysis: one-way ANOVA, *p < 0.01).
Three independent experiments were performed and all reactions were performed in triplicate. b Canine osteoblasts or OSA16 cells were transduced
with either empty vector or pre-miR-9-3 lentivirus vector and cell proliferation was analyzed at 24, 48, and 72 h using the CyQUANT method.
Non-transduced osteoblasts or OSA16 cells served as non-treated controls. Three independent experiments were performed and all samples were
seeded in triplicate wells. Values are reported as percentage of untransduced control cells. c Canine osteoblasts or OSA16 cells transduced with
either empty vector or pre-miR-9-3 lentivirus were assessed for apoptosis at 24 and 48 h by measuring active caspase-3/7 using the SensoLyte®
Homogeneous AMC Caspase-3/7 Assay kit. Relative fluorescence units are reported after subtraction of fluorescence levels of wells with medium only
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human OS tumors compared to paired non-cancerous
bone tissues [45]. Furthermore, increased serum miR-9
concentrations in human OS patients and miR-9 expres-
sion in primary OS tumors strongly correlates with tumor
size, clinical stage, distant metastasis, and poor clinical
outcome [45, 56]. In concordance with data implicating
miR-9 in promoting the aggressive biological behavior of
osteoblasts, most of the malignant canine OS cell lines
evaluated in this study expressed significantly higher levels
of miR-9 compared to that observed in normal canine
osteoblast cells and primary osteoblast cultures.
MiR-9 is known to confer multiple, often divergent,
functions to various cell types including inhibition of
human ovarian tumor cell growth [57] and stimulation of
proliferation of gastric cancer cell lines [58]. Indeed, a
common theme has emerged where miRNA effects are
often cell type/tissue specific and may influence several
aspects of cellular behavior. [11, 12]. Previous studies have
Fig. 5 MiR-9 enhances invasion and migration in normal canine osteoblasts and OS cell lines. a The invasive capacity of normal canine
osteoblasts or OSA16 cells transduced with either empty vector or pre-miR-9-3 lentivirus was evaluated using standard Matrigel invasion assays.
Cells (5 × 104) were plated in serum free medium and transferred onto cell culture inserts coated with Matrigel® for 24 h. After incubation, cells
remaining on the upper surface of the insert membrane were wiped away using a cotton swab, and cells that had migrated to the lower surface
were stained with crystal violet and counted in ten independent 20x hpf for each sample. Three independent experiments were performed and
all assays were performed in triplicate wells (Bars: SD. Statistical analysis: one-way ANOVA, *p < 0.001). b Cell migration was assessed in canine
osteoblasts transduced with either empty vector or pre-miR-9-3 lentivirus using standard wound-healing assays. Cells were seeded in complete
medium and grown until confluent in 6-well plates. A gap was created using a P200 pipette tip, and medium was replaced with serum-free
medium. After 24 h, cell migration was evaluated by digital photography. c Canine OSA8 cells were transduced with miRZip-9 (anti-miR-9) or
scramble vector and miR-9 levels were assessed by real-time PCR to confirm transduction efficiency (*p < 0.0009). Cell invasion was assessed in
canine OSA8 cells transduced with scramble or miRZip-9 (anti-miR-9) lentivirus using standard Matrigel invasion assays as described above.
Three independent experiments were performed and all assays were performed in triplicate wells (*p < 0.0002). d Cell migration was assessed
in OSA8 cells transduced with miRZip-9 (anti-miR-9) or scramble vector using standard wound-healing assays as described above. After 20 h,
cell migration was evaluated by digital photography
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identified a role for miR-9 in promoting the metastatic
phenotype in human breast cancer cell lines through its
ability to enhance cell invasion and enable otherwise non-
metastatic breast tumor cells to form pulmonary micro-
metastases in mice [59]. Furthermore, miR-9 expression
levels were shown to be significantly increased in distant
metastases compared to corresponding primary tumors,
suggesting that miR-9 is directly involved in the metastatic
process [60, 61]. With respect to the role of miR-9 in
spontaneous canine neoplasia, we have previously shown
that overexpression of miR-9 is associated with aggressive,
metastatic behavior in primary canine mast cell tumors
and that enforced expression of miR-9 expression in nor-
mal and malignant mast cells enhances their invasive cap-
acity and induces a pattern of gene expression that
promotes cellular invasion [28]. In murine pre-osteoblasts
and pluripotent stem cells, miR-9 expression is reduced
following BMP2-induced osteoblastic differentiation, im-
plying that miR-9 may be an important regulatory factor
in osteoblastic differentiation [62, 63]. Other studies have
shown that in human HOS and U2OS osteosarcoma cells
express significantly higher levels of miR-9 compared to
human mesenchymal stem cells or normal osteoblasts and
demonstrate a functional role for miR-9 regulating osteo-
sarcoma cell proliferation by targeting the GCIP tumor
suppressor protein [64]. However, our data indicate that
while enforced miR-9 expression in normal canine osteo-
blasts and the OSA16 cell line enhanced cellular invasion
and migration, miR-9 had no impact on cellular prolifera-
tion or viability. Furthermore, transduction of the canine
OSA8 cell line expressing high basal levels of miR-9 with
an anti-miR-9 construct subsequently decreased invasion
and migration, supporting the assertion that miR-9
promotes a metastatic phenotype in osteoblasts and OS
cell lines.
To gain further mechanistic insight into miR-9-
dependent cell signaling events that may promote the in-
vasive phenotype of osteoblasts, we evaluated the prote-
omic and gene expression profiles of canine osteoblasts
expressing high levels of miR-9. We did not identify pre-
dicted miR-9 targets among the proteins that were found
to be down-regulated in our proteomic analysis. One
possible explanation for this is that while the miRNA
target prediction tools (TargetScan, miRanda, miRWalk,
PicTar) used in this study identified miR-9 canonical
binding sites in the 3’UTR, because miRNAs are known
to target other non-canonical sites, coding regions or 5’
UTRs these would not be detected in our analysis. Inter-
estingly, our proteomic analysis identified several pro-
teins upregulated by miR-9, including gelsolin, an actin
filament severing and capping protein implicated in pro-
moting the metastatic phenotype [46, 65]. The import-
ance of gelsolin in actin dynamics has been explored in
gelsolin null (GSN-) dermal fibroblasts, which show a
marked reduction in motility and ruffling activity in re-
sponse to serum or EGF stimulation compared to wild-
type fibroblasts [66]. In contrast, overexpression of gel-
solin in NIH 3 T3 fibroblasts leads to a dose-dependent
increase in translocation motility as assessed by tissue
culture wound closure and filter transmigration assays
[67]. Gelsolin-null (GSN-) mice demonstrate platelet
shape changes causing prolonged bleeding times, de-
layed neutrophil migration, and blunted fibroblast re-
sponses, establishing the requirement of gelsolin for
rapid motility in cell types involved in stress responses
in vivo [68]. Importantly, elevated levels of gelsolin
Table 3 Proteins identified by two-dimensional electrophoresis and capillary-liquid chromatography-tandem mass spectrometry
Spot # t-test Av Δ Acc # Description pI Mass Sa Mb
291 0.038 −1.4 gi|73997540 PREDICTED: ELKS/Rab6-interacting/CAST family
member 1 isoformX1 [Canis lupus familiaris]
5.69 128164 147 2
919 0.007 −1.1 gi|73980394 PREDICTED: protein disulfide-isomerase A6
[Canis lupus familiaris]
4.97 48667 906 11
961 0.021 −1.3 No ID
1080 0.034 1.1 No ID
1384 0.033 1.2 No ID
1609 0.027 1.4 gi|5031635 cofilin-1 [Canis lupus familiaris] 8.52 19715 343 3
1617 0.03 1.2 No ID
1872 0.029 1.2 gi|478533920 PREDICTED: 60S acidic ribosomal protein P2
[Ceratotherium simum simum]
4.44 11772 364 4
1925 0.052 1.2 gi|350582724 PREDICTED: 14-3-3 protein theta isoform 2 [Sus scrofa] 4.67 28075 983 12
1935 0.008 1.2 gi|545518174 PREDICTED: gelsolin [Canis lupus familiaris] 8.49 95129 609 8
aThe protein score is derived from Mascot and provides an indication of how well the peptides matched the indicated protein sequence. The actual score is
calculated by the following equation: protein score = −10*Log(P), where P is the probability that the protein match is a random event. Scores above 100 indicate
that p < 0.05
bThe protein match score indicates the number of unique peptides that matched the sequence of the identified protein. Two unique peptide matches to a
protein sequence confirms the identity of a prot
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expression have been detected in human non-small cell
lung [69], colorectal [70], and pancreatic carcinomas
[71] and depletion of gelsolin using siRNAs in pancre-
atic, prostate, colorectal, and breast carcinoma cell lines
caused a marked reduction in cell motility [72].
We confirmed significant upregulation of gelsolin
transcript and protein in normal osteoblasts expressing
Fig. 6 MiR-9 alters gelsolin expression in normal canine osteoblasts and
OS cell lines. a Protein lysates were generated from normal canine
osteoblasts stably transduced with either empty vector (EV) or pre-miR-9-3
(miR-9) lentivirus and canine OSA8 cells stably transduced with miRZip-9
(anti-miR-9) or scramble vector control. Protein lysates were separated via
SDS-PAGE and western blotting for gelsolin and β-actin was performed.
b Canine osteoblasts expressing pre-miR-9-3 lentivirus or empty vector
control were collected and real-time PCR for gelsolin and (c) TGFBI was
performed (Bars: SD. Statistical analysis: one-way ANOVA, *p< 0.01). Three
independent experiments were performed using cells from 3 separate
transduction experiments and all reactions were performed in triplicate
Fig. 7 Gelsolin shRNA decreases cell invasion and migration in canine
OSA8 cells. a Protein lysates were generated from canine OSA8 cells
stably transduced with either pLK0.1-scramble-hygroB (Scr) control
vector or pLK0.1-shGSN-hygroB (shGSN) lentivirus and positive clones
were selected for with Hygromycin B. Protein lysates were separated
via SDS-PAGE and western blotting for gelsolin (GSN) and β-actin was
performed to confirm efficiency of GSN knockdown. b Canine OSA8
cells expressing pLK0.1-shGSN-hygroB or scramble control were
collected and real-time PCR for gelsolin was performed (Bars: SD.
Statistical analysis: one-way ANOVA, *p < 0.01). c The invasive capacity
of OSA8 cells transduced with either pLK0.1-scramble-hygroB control
vector or pLK0.1-shGSN-hygroB lentivirus was evaluated using standard
Matrigel invasion assays. Cells (5 × 104) were plated in serum free
medium and transferred onto cell culture inserts coated with Matrigel®
for 24 h. After incubation, cells remaining on the upper surface of the
insert membrane were wiped away using a cotton swab, and cells that
had migrated to the lower surface were stained with crystal violet
and counted in ten independent 20x hpf for each sample. Three
independent experiments were performed using cells from 3
separate transduction experiments and all reactions were
performed in triplicate
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miR-9 and found that knockdown of miR-9 in the OSA8
cell line resulted in decreased expression of gelsolin with
a concomitant decrease in cell invasion and migration.
Given the established role of gelsolin in the regulation of
actin polymerization and cycling, our data indicate that
miR-9 may enhance invasion in canine neoplastic
osteoblasts, in part, through increased expression of this
protein. To further investigate the effects of gelsolin on
osteoblast motility, transduction of OSA8 cells with
GSN shRNA downregulated GSN expression resulting in
a subsequent decrease in cell invasion. Taken together,
our findings support the idea that miR-9 induces a
pattern of gene expression that promotes increased cell
motility and invasiveness and suggest that miR-9-
mediated up-regulation of gelsolin may in part play a
role in mediating the biological consequences of miR-9.
As miR-9 overexpression is associated with upregulation
of gelsolin at the transcript and protein level, it is pos-
sible that miR-9 alters transcription factors responsible
for repressing gelsolin expression. Alternatively, miR-9
may downregulate epigenetic factors that suppress
gelsolin expression through DNA methylation or acetyl-
ation. Indeed, RNA sequencing of osteoblasts possessing
enforced expression of miR-9 demonstrated that miR-9
modulated the expression of several genes, including
downregulation of putative miR-9 targets whose
transcripts contain 3’-UTR consensus binding sites for
miR-9. Among these predicted targets, several transcrip-
tion factors (HOX6B, TCF19) showed significant de-
creases in expression and putative HOXB binding sites
were found in the promoter region of the canine gelsolin
(GSN) gene, indicating a possible mechanism through
which miR-9 induces upregulation of gelsolin.
Our data also show that miR-9 negatively regulates the
expression of several other factors that may cooperatively
enhance invasion and motility in normal osteoblasts. For
example, miR-9 overexpression in normal osteoblasts
downregulated expression of TGF-β-induced (TGFBI), an
extracellular matrix protein and known mediator of
osteoblast adhesion by virtue of its interactions with αvβ3
and αvβ5 integrin heterodimers [73]. TGFBI deficiency
predisposes mice to spontaneous tumor development
(lymphoma, lung adenocarcinoma) and TGFBI−/− mice
have reduced body size, bone mass, bone size, and de-
creased periosteal bone formation, suggesting that TGFBI
functions as a tumor suppressor and plays an important
role in regulating bone homeostasis in vivo [74, 75]. A
functional approach would be required to confirm direct
targeting of putative gene targets by miR-9 and validate
regulation of gene expression by miR-9. Furthermore, loss
or gain of function studies evaluating components of the
miR-9 regulatory circuit would further elucidate their
contribution to osteoblast invasion and represents an
ongoing area of investigation.
Conclusions
Our data demonstrate that a unique miRNA expression
signature is associated with spontaneously occurring ca-
nine OS. Furthermore, primary canine OS tumor speci-
mens and OS cell lines express significantly higher levels
of miR-9 compared to normal canine osteoblasts and pri-
mary osteoblast cultures. These results are concordant
with data generated in human OS tumors, suggesting that
dysregulation of miR-9 may be fundamental to the disease
process in both species. Our data indicate that overexpres-
sion of miR-9 in normal osteoblasts and OS cell lines
contributes to the aggressive biological behavior of OS as
demonstrated by enhanced cellular invasiveness and mo-
tility and alteration in gene and protein expression profiles
associated with cellular invasion, thereby promoting the
metastatic phenotype. Furthermore, the actin filament-
severing protein gelsolin was identified as a mediator of
the miR-9 induced invasive phenotype in normal osteo-
blasts and OS cell lines, providing a potential mechanism
for the relationship between miR-9 expression and metas-
tasis. Future work to more thoroughly characterize how
miR-9 expression imparts a metastatic phenotype in OS is
ongoing with the ultimate goal of identifying novel targets
for therapeutic intervention.
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Additional file 1: Table S1. Clinical Patient Data. (DOCX 18 kb)
Additional file 2: Figure S1. MiRNA expression profiling of normal
canine tissues using the nanoString nCounter platform. MicroRNA
expression was evaluated in normal canine tissues (brain cortex, liver,
lymph node, kidney, skeletal muscle, spleen, thyroid; N = 3 per tissue)
using the Human (V2) miRNA Expression Assay CodeSet. Hierarchical
clustering was performed for 110 miRNAs demonstrating unique
tissue-specific expression profiles as determined by one-way ANOVA
comparison test (p < 1e-06). (TIF 5836 kb)
Additional file 3: Figure S2. Validation of nanoString profiling data in
normal canine tissues. Real-time PCR was performed to independently
validate changes in tissue-specific miRNA expression in normal canine
tissues identified by the nanoString nCounter system. Real-time PCR
confirmed differential expression of 5 representative miRNAs (miR-1, miR-9,
miR-10b, miR-122, miR-200c) in normal canine tissues (brain cortex, liver,
lymph node, kidney, skeletal muscle, spleen, thyroid; N = 3 per tissue)
(Bars: SD. Statistical analysis: one-way ANOVA, *p < 0.05). Three independent
experiments were performed and all reactions were run in triplicate.
(PNG 163 kb)
Additional file 4: Figure S3. Expression of bone markers in primary
canine osteoblast cultures. (A) RNA was collected from five canine
osteoblast (Ob) cultures established from canine patients, normal canine
osteoblast cells (K9 Ob), and a canine OSA cell line (OSA8) and RT-PCR was
performed for alkaline phosphatase (ALP), bone morphogenic protein-2
(BMP2), osteopontin (OP), and GAPDH. NTC = non-template control. (B)
Primary canine osteoblast cultures were evaluated for ALP expression using
immunocytochemistry (Sigma). Upper left panel: horse neutrophils (positive
control), Upper right panel: stem cells cultured in non-differentiating
conditions (negative control), Lower two panels: expression of ALP in
differentiated primary canine osteoblast cultures. (TIF 9327 kb)
Additional file 5: Figure S4. 2-dimensional difference-in-gel
electrophoresis (A) Representative gel image showing Cy3 (Ob-miR-9)
and Cy5-labeled (Ob-EV) proteins that were isoelectric focused on pH
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strips (3-10), separated by size using SDS-PAGE, and visualized using a
Typhoon 9400 variable mode imager. A merged image of the Cy3 and
Cy5-labeled proteins is shown. Proteins with greater abundance in the
miR-9-transfected sample appear green and proteins with greater
abundance in the EV-transfected samples appear red. Proteins that did
not change relative abundance between the two samples appear yellow.
(B) Master gel image of spots exhibiting statistically significantly protein
expression changes. Core protein spots of interest were excised from
preparative gels stained with Lava purple general protein stain, digested
with trypsin, and subject to capillary-liquid chromatography-tandem mass
spectrometry analysis. The spots that were cored for subsequent protein
identification are outlined and annotated (the number for each spot is
the master spot number and corresponds to the Spot # listed in Table 3).
(TIF 8721 kb)
Additional file 6: Table S2. Altered gene transcripts in canine
osteoblasts overexpressing miR-9 (DOCX 18 kb)
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